Advertisement

Neuroscience and Behavioral Physiology

, Volume 42, Issue 2, pp 123–127 | Cite as

Treatment of Exacerbations of Multiple Sclerosis without the Use of Corticosteroids: The Role of Metabolic and Antioxidant Therapy

  • G. N. Bisaga
  • M. M. Odinak
  • A. N. Boiko
  • Yu. B. Melnik
  • N. F. Popova
Article

A multicenter randomized post-registration case-control study was performed with 94 patients with relapsing-remitting and secondary progressive multiple sclerosis (MS) in exacerbation. The patients were divided into two groups: group 1 (n = 53) received Cytoflavin and basal therapy (Trental and group B vitamins), while group 2 (n = 41) received only basal therapy. After five days, treatment results were used to further divide each group into two subgroups: patients of subgroup 1A (n = 22), with clear positive treatment effects, continued to receive Cytoflavin and basal therapy; group 1B (n = 31) additionally received corticosteroid (methipred) pulse therapy; subgroup 2A (n = 14), with significant positive effects, continued to receive basal therapy; group 2B (n = 27) additionally received corticosteroid pulse therapy. The complex treatment, with Cytoflavin, Trental, group B vitamins, and corticosteroids, was found to be safe and well tolerated. The positive effects of including Cytoflavin in complex treatment consisted of a reduction in the need for corticosteroids: 41.5% of patients receiving Cytoflavin no longer needed them, compared with 34% of patients receiving only basal therapy. Patients given Cytoflavin showed more significant regression of neurological symptomatology on the EDSS than the group not given Cytoflavin; there were no patients with no treatment response; lipid peroxidation and anti-myelin basic protein antibody levels decreased; cognitive functions improved.

Keywords

multiple sclerosis exacerbation Cytoflavin metabolic treatment antioxidant treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    V. V. Afanasiev and I. Yu. Lukyanova, Features of the Use of Cytoflavin in Current Clinical Practice [in Russian], St. Petersburg (2010).Google Scholar
  2. 2.
    V. B. Gavrilov, A. R. Gavrilova, and L. M. Mazhul, “Analysis of methods for estimating serum lipid peroxidation products with thiobarbituric acid,” Vopr. Med. Khim., 33, No. 1, 118–122 (1987).PubMedGoogle Scholar
  3. 3.
    E. E. Dubinina, S. O. Burmistrov, D. A. Khodov, and I. S. Porotov, “Oxidative modification of human serum proteins. Assay methods,” Vopr. Med. Khim., 41, No. 1, 24–26 (1995).Google Scholar
  4. 4.
    A. L. Kovalenko, M. N. Bizenkova, V. V. Bul’on, et al., “Pathogenetic basis and pharmacotherapeutic efficacy of the use of Cytoflavin in acute cerebral ischemia,” SPbMGA, 3, 79–83 (2006).Google Scholar
  5. 5.
    M. M. Odinak, G. N. Gisaga, and I. V. Zarubina, “New approaches to antioxidant therapy in multiple sclerosis,” Zh. Nevrol. Psikhiat., Special issue on Multiple Sclerosis, 72–75 (2002).Google Scholar
  6. 6.
    I. D. Stalnaya and T. G. Gorishvili, “A method for estimating malondialdehye with thiobarbituric acid,” in: Current Methods in Biochemistry [in Russian], V. N. Orekhovich (ed.), Meditsina, Moscow (1977), pp. 66–68.Google Scholar
  7. 7.
    J. F. Kurtzke, “Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, 33, 1444–1452 (1983).PubMedGoogle Scholar
  8. 8.
    P. R. Lyons, P. K. Newman, and M. Saunders, “Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects,” J. Neurol. Neurosurg. Psychiat., 51, No. 2, 285–287 (1988).PubMedCrossRefGoogle Scholar
  9. 9.
    K. M. Myhr and S. I. Mellgren, “Corticosteroids in the treatment of multiple sclerosis,” Acta Neurol. Scand., Suppl., 73–80 (2009).Google Scholar
  10. 10.
    M. Namaka, R. Vandenbosch, R. Gill, et al., “Corticosteroids and multiple sclerosis: to treat or not to treat,” Can. Pharm. J., 138, No. 6, 1–13 (2005).Google Scholar
  11. 11.
    C. H. Polman, S. C. Reingold, G. Edan, et al., “Diagnostic criteria for multiple sclerosis: 2005 revision to the McDonald Criteria,” Ann. Neurol., 58, 840–846 (2005).PubMedCrossRefGoogle Scholar
  12. 12.
    C. M. Poser, D. W. Paty, L. Scheinberg, et al., “New diagnostic criteria for multiple sclerosis: guidelines for research protocols,” Ann. Neurol., 13, 227–231 (1983).PubMedCrossRefGoogle Scholar
  13. 13.
    A. Scalfari, A. Neuhaus, A. Degenhardt, et al., “The natural history of multiple sclerosis: a geographically based study. 10: relapses and long-term disability,” Brain, 133, No. 7, 1914–1929 (2010).Google Scholar
  14. 14.
    C. A. Tyson, K. D. Lunan, and R. I. Stephens, “Age-related differences in G-SH-shuttle enzymes in NO2 or O3 exposed rat lungs,” Arch. Env. Health, 37, No. 3, 167–176 (1982).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2011

Authors and Affiliations

  • G. N. Bisaga
    • 1
  • M. M. Odinak
    • 1
  • A. N. Boiko
    • 2
  • Yu. B. Melnik
    • 1
  • N. F. Popova
    • 2
  1. 1.S. M. Kirov Military Medical Academy, Nervous Diseases ClinicSt. PetersburgRussia
  2. 2.Moscow City Multiple Sclerosis CenterMoscowRussia

Personalised recommendations